Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
synthetic heparinoids	1236	104993-28-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fondaparinux fondaparin heparin pentasaccharide fondaparinux sodium arixtra fondaparin sodium	Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Molecular weight: 1508.22 Formula: C31H53N3O49S8 CLOGP: -10.96 LIPINSKI: 3 HAC: 52 HDO: 19 TPSA: 805.48 ALOGS: -2.28 ROTB: 27

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fondaparinux
fondaparin
heparin pentasaccharide
fondaparinux sodium
arixtra
fondaparin sodium

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Molecular weight: 1508.22
Formula: C31H53N3O49S8
CLOGP: -10.96
LIPINSKI: 3
HAC: 52
HDO: 19
TPSA: 805.48
ALOGS: -2.28
ROTB: 27

Drug dosage:

Dose	Unit	Route
2.50	mg	P

ADMET properties:

Property	Value	Reference
CL (Clearance)	0.07 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.21 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	19.30 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution)	0.14 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Dec. 7, 2001	FDA	MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	699.34	18.94	238	10855	38810	90578544
Muscle haemorrhage	379.95	18.94	87	11006	3259	90614095
Pulmonary embolism	314.94	18.94	197	10896	130623	90486731
Anaemia	255.72	18.94	262	10831	352540	90264814
Heparin-induced thrombocytopenia	203.27	18.94	58	11035	5254	90612100
Shock haemorrhagic	193.11	18.94	68	11025	12177	90605177
Cerebral haemorrhage	189.84	18.94	90	11003	34432	90582922
Deep vein thrombosis	164.39	18.94	115	10978	91505	90525849
Haemorrhage	155.49	18.94	100	10993	69269	90548085
Haemoglobin decreased	152.18	18.94	139	10954	161817	90455537
Incorrect product administration duration	149.62	18.94	64	11029	19258	90598096
Intra-abdominal haematoma	141.49	18.94	36	11057	2108	90615246
Melaena	136.05	18.94	72	11021	34725	90582629
Post procedural haemorrhage	135.44	18.94	48	11045	8750	90608604
Post procedural haematoma	125.77	18.94	30	11063	1342	90616012
Retroperitoneal haematoma	107.72	18.94	32	11061	3336	90614018
Subcutaneous haematoma	106.66	18.94	28	11065	1855	90615499
Subdural haematoma	99.51	18.94	46	11047	16599	90600755
Thrombocytopenia	94.71	18.94	122	10971	208603	90408751
Abdominal wall haematoma	90.69	18.94	28	11065	3324	90614030
Hypersensitivity myocarditis	88.20	18.94	17	11076	269	90617085
Haematemesis	86.52	18.94	53	11040	33673	90583681
Thrombosis	80.94	18.94	69	11024	73182	90544172
Incision site haematoma	78.13	18.94	13	11080	83	90617271
Compartment syndrome	77.41	18.94	24	11069	2888	90614466
Haemorrhage subcutaneous	73.78	18.94	24	11069	3372	90613982
Blood loss anaemia	73.27	18.94	32	11061	10108	90607246
Sinobronchitis	67.75	18.94	16	11077	685	90616669
Gastrointestinal haemorrhage	59.61	18.94	64	11029	90184	90527170
Tooth erosion	56.55	18.94	13	11080	494	90616860
Extradural haematoma	54.79	18.94	17	11076	2051	90615303
Hypovolaemic shock	53.25	18.94	23	11070	7071	90610283
Intra-abdominal haemorrhage	50.57	18.94	17	11076	2645	90614709
Allergic sinusitis	50.27	18.94	16	11077	2097	90615257
Incision site haemorrhage	48.88	18.94	12	11081	606	90616748
Fatigue	48.76	18.94	42	11051	1153981	89463373
Thrombocytosis	43.88	18.94	20	11073	6981	90610373
Toxic skin eruption	43.56	18.94	26	11067	15748	90601606
Pulpitis dental	42.73	18.94	12	11081	1024	90616330
Renal failure	40.72	18.94	64	11029	130943	90486411
Leukocytosis	40.07	18.94	32	11061	30958	90586396
Skin necrosis	39.34	18.94	25	11068	16916	90600438
Neurological decompensation	38.77	18.94	15	11078	3486	90613868
Drug interaction	38.12	18.94	96	10997	276357	90340997
Autoimmune thyroiditis	37.45	18.94	17	11076	5876	90611478
Abdominal discomfort	36.69	18.94	7	11086	477321	90140033
Cerebral haematoma	35.82	18.94	15	11078	4274	90613080
Haemoperitoneum	35.14	18.94	14	11079	3514	90613840
Injection site haematoma	34.84	18.94	17	11076	6905	90610449
Red blood cell count decreased	34.40	18.94	35	11058	46316	90571038
Wound haemorrhage	34.32	18.94	13	11080	2854	90614500
Abdominal wall haemorrhage	33.63	18.94	7	11086	166	90617188
Shock	33.60	18.94	28	11065	28750	90588604
Intraventricular haemorrhage	32.49	18.94	12	11081	2457	90614897
Weight increased	32.39	18.94	6	11087	417921	90199433
Oesophageal candidiasis	32.08	18.94	16	11077	6813	90610541
Venous thrombosis limb	31.94	18.94	13	11080	3449	90613905
Haematocrit decreased	31.79	18.94	32	11061	41800	90575554
Gastric haemorrhage	31.48	18.94	16	11077	7087	90610267
Splenic rupture	31.05	18.94	10	11083	1361	90615993
Adrenal haemorrhage	30.66	18.94	8	11085	517	90616837
Periodontitis	30.59	18.94	13	11080	3840	90613514
Retroperitoneal haemorrhage	29.91	18.94	12	11081	3068	90614286
Drug hypersensitivity	29.49	18.94	10	11083	463599	90153755
Pain	29.45	18.94	48	11045	996293	89621061
Hepatic infarction	28.54	18.94	8	11085	678	90616676
Contraindicated product administered	28.54	18.94	3	11090	320136	90297218
Joint swelling	28.49	18.94	13	11080	503287	90114067
Rectal haemorrhage	27.91	18.94	42	11051	82702	90534652
Insomnia	27.59	18.94	4	11089	333470	90283884
Headache	26.97	18.94	40	11053	862706	89754648
Rash maculo-papular	26.96	18.94	29	11064	40904	90576450
Sinusitis	26.42	18.94	5	11088	343083	90274271
Procedural haemorrhage	26.34	18.94	11	11082	3113	90614241
Hepatic function abnormal	25.70	18.94	30	11063	46258	90571096
Nasopharyngitis	25.50	18.94	9	11084	407095	90210259
Nasal polyps	25.12	18.94	16	11077	10864	90606490
Hypoperfusion	24.69	18.94	9	11084	1775	90615579
Spinal cord compression	24.53	18.94	12	11081	4899	90612455
Postoperative wound complication	24.42	18.94	8	11085	1149	90616205
Abdominal pain	24.05	18.94	104	10989	395617	90221737
Prothrombin level decreased	23.97	18.94	7	11086	687	90616667
Eosinophilia	23.86	18.94	23	11070	28510	90588844
Hemiplegia	23.74	18.94	18	11075	16142	90601212
Platelet count increased	23.74	18.94	20	11073	20839	90596515
Musculoskeletal stiffness	23.52	18.94	4	11089	296528	90320826
Haematuria	23.44	18.94	25	11068	34912	90582442
Haemoptysis	22.63	18.94	24	11069	33296	90584058
Arthralgia	22.51	18.94	38	11055	778484	89838870
Depression	21.86	18.94	5	11088	300596	90316758
Post procedural swelling	21.79	18.94	6	11087	476	90616878
Haemodynamic instability	21.63	18.94	15	11078	11724	90605630
Breast haematoma	21.19	18.94	5	11088	213	90617141
Traumatic haematoma	20.98	18.94	8	11085	1787	90615567
Ecchymosis	20.97	18.94	15	11078	12308	90605046
Gastric ulcer haemorrhage	20.77	18.94	11	11082	5300	90612054
Haematoma muscle	20.75	18.94	8	11085	1842	90615512
Bullous haemorrhagic dermatosis	20.67	18.94	5	11088	237	90617117
Nephropathy toxic	20.58	18.94	15	11078	12673	90604681
Vulvovaginal injury	20.53	18.94	6	11087	590	90616764
Spontaneous haematoma	20.44	18.94	7	11086	1151	90616203
Pallor	20.41	18.94	23	11070	34142	90583212
Pneumonitis	20.26	18.94	26	11067	44144	90573210
Brain herniation	20.20	18.94	10	11083	4190	90613164
Pelvic venous thrombosis	20.14	18.94	8	11085	1993	90615361
Small intestinal haemorrhage	19.16	18.94	8	11085	2263	90615091
Stomatitis	19.13	18.94	5	11088	274693	90342661
Epistaxis	19.08	18.94	36	11057	85089	90532265

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	263.64	19.72	119	7513	27904	42585799
Incorrect product administration duration	187.91	19.72	61	7571	5819	42607884
Heparin-induced thrombocytopenia	142.37	19.72	51	7581	6546	42607157
Muscle haemorrhage	132.61	19.72	43	7589	4082	42609621
Shock haemorrhagic	130.83	19.72	62	7570	16180	42597523
Pulmonary embolism	117.64	19.72	125	7507	119487	42494216
Cerebral haemorrhage	105.65	19.72	73	7559	38893	42574810
Anaemia	98.62	19.72	178	7454	280100	42333603
Haemorrhage	93.04	19.72	81	7551	60482	42553221
Post procedural haemorrhage	76.35	19.72	36	7596	9276	42604427
Adrenal haemorrhage	68.03	19.72	15	7617	317	42613386
Haematoma muscle	59.42	19.72	20	7612	2130	42611573
Ureteric compression	57.96	19.72	13	7619	298	42613405
Post procedural haematoma	56.56	19.72	18	7614	1607	42612096
Melaena	55.81	19.72	50	7582	38696	42575007
Subdural haematoma	52.66	19.72	39	7593	23099	42590604
Retroperitoneal haemorrhage	51.93	19.72	20	7612	3135	42610568
Tumour fistulisation	51.21	19.72	10	7622	113	42613590
Haematuria	49.04	19.72	56	7576	57743	42555960
Haemoglobin decreased	47.45	19.72	85	7547	132386	42481317
Gastroduodenal ulcer	47.20	19.72	13	7619	702	42613001
Abdominal wall haematoma	46.52	19.72	17	7615	2305	42611398
Thrombocytopenia	46.45	19.72	104	7528	190175	42423528
Deep vein thrombosis	43.67	19.72	61	7571	76896	42536807
Haematemesis	43.54	19.72	39	7593	30160	42583543
Retroperitoneal haematoma	42.01	19.72	17	7615	3034	42610669
Thrombocytosis	40.80	19.72	19	7613	4756	42608947
Extradural haematoma	39.05	19.72	13	7619	1338	42612365
Pyelocaliectasis	38.51	19.72	13	7619	1396	42612307
Intra-abdominal haematoma	37.04	19.72	13	7619	1568	42612135
Tumour perforation	36.88	19.72	10	7622	509	42613194
Device related bacteraemia	34.23	19.72	10	7622	669	42613034
Gastrointestinal haemorrhage	34.06	19.72	62	7570	97664	42516039
Thrombosis	34.03	19.72	51	7581	68460	42545243
Spinal cord haemorrhage	31.35	19.72	8	7624	321	42613382
Toxicity to various agents	30.28	19.72	3	7629	229133	42384570
Bullous haemorrhagic dermatosis	28.73	19.72	6	7626	97	42613606
Primary adrenal insufficiency	26.79	19.72	7	7625	309	42613394
Haemorrhage intracranial	26.36	19.72	23	7609	17169	42596534
Venous thrombosis	25.30	19.72	13	7619	4022	42609681
Haemorrhagic stroke	25.19	19.72	16	7616	7386	42606317
Pericardial mass	24.97	19.72	4	7628	12	42613691
Spontaneous haematoma	24.75	19.72	8	7624	750	42612953
Cerebral haematoma	23.90	19.72	14	7618	5596	42608107
Lumbosacral plexus injury	23.88	19.72	4	7628	17	42613686
Upper gastrointestinal haemorrhage	23.41	19.72	28	7604	30271	42583432
Altered state of consciousness	22.54	19.72	27	7605	29232	42584471
Autoimmune heparin-induced thrombocytopenia	20.50	19.72	4	7628	45	42613658
Gastric haemorrhage	20.13	19.72	16	7616	10499	42603204
Intra-abdominal haemorrhage	20.01	19.72	10	7622	2918	42610785
Haemarthrosis	19.78	19.72	11	7621	3987	42609716

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	733.37	18.87	280	14447	58196	110516376
Pulmonary embolism	344.64	18.87	260	14467	214214	110360358
Heparin-induced thrombocytopenia	316.22	18.87	99	14628	11325	110563247
Muscle haemorrhage	315.02	18.87	88	14639	6781	110567791
Cerebral haemorrhage	264.58	18.87	142	14585	64826	110509746
Shock haemorrhagic	255.70	18.87	106	14621	27141	110547431
Anaemia	251.31	18.87	335	14392	546751	110027821
Incorrect product administration duration	193.16	18.87	80	14647	20418	110554154
Haemorrhage	183.65	18.87	135	14592	106557	110468015
Deep vein thrombosis	167.61	18.87	143	14584	139744	110434828
Post procedural haemorrhage	137.60	18.87	58	14669	15454	110559118
Melaena	134.31	18.87	94	14633	68663	110505909
Post procedural haematoma	126.43	18.87	35	14692	2604	110571968
Haemoglobin decreased	113.20	18.87	152	14575	248575	110325997
Intra-abdominal haematoma	112.63	18.87	34	14693	3438	110571134
Haematemesis	111.24	18.87	79	14648	59029	110515543
Thrombocytopenia	108.14	18.87	178	14549	348707	110225865
Abdominal wall haematoma	103.70	18.87	36	14691	5669	110568903
Subdural haematoma	98.35	18.87	61	14666	36393	110538179
Adrenal haemorrhage	95.06	18.87	22	14705	790	110573782
Retroperitoneal haematoma	93.65	18.87	34	14693	6097	110568475
Thrombosis	92.85	18.87	92	14635	108570	110466002
Hypersensitivity myocarditis	83.20	18.87	17	14710	336	110574236
Subcutaneous haematoma	82.68	18.87	26	14701	3010	110571562
Extradural haematoma	75.98	18.87	25	14702	3344	110571228
Haematoma muscle	75.08	18.87	26	14701	4064	110570508
Sinobronchitis	72.37	18.87	16	14711	466	110574106
Haematuria	72.23	18.87	71	14656	82934	110491638
Blood loss anaemia	72.18	18.87	39	14688	17986	110556586
Thrombocytosis	63.56	18.87	30	14697	10414	110564158
Ureteric compression	61.66	18.87	13	14714	301	110574271
Drug interaction	61.05	18.87	175	14552	500008	110074564
Gastrointestinal haemorrhage	60.23	18.87	91	14636	165427	110409145
Retroperitoneal haemorrhage	58.23	18.87	24	14703	6041	110568531
Incision site haemorrhage	54.61	18.87	15	14712	1083	110573489
Pyelocaliectasis	54.33	18.87	15	14712	1104	110573468
Tumour fistulisation	52.45	18.87	10	14717	136	110574436
Tooth erosion	52.04	18.87	12	14715	424	110574148
Allergic sinusitis	51.63	18.87	16	14711	1765	110572807
Hypovolaemic shock	51.37	18.87	29	14698	14554	110560018
Compartment syndrome	48.77	18.87	21	14706	5889	110568683
Bullous haemorrhagic dermatosis	48.63	18.87	11	14716	356	110574216
Gastroduodenal ulcer	47.07	18.87	13	14714	958	110573614
Skin necrosis	45.72	18.87	31	14696	21481	110553091
Haemorrhage subcutaneous	43.48	18.87	19	14708	5520	110569052
Injection site haematoma	41.53	18.87	18	14709	5128	110569444
Gastric haemorrhage	41.32	18.87	26	14701	15889	110558683
Brain herniation	40.65	18.87	21	14706	8842	110565730
Wound haemorrhage	39.63	18.87	17	14710	4721	110569851
Weight increased	38.90	18.87	5	14722	419639	110154933
Toxic skin eruption	38.89	18.87	31	14696	27484	110547088
Nasopharyngitis	38.30	18.87	4	14723	394357	110180215
Spinal cord haemorrhage	38.25	18.87	10	14717	598	110573974
Spontaneous haematoma	38.07	18.87	13	14714	1948	110572624
Tumour perforation	37.66	18.87	10	14717	635	110573937
Haemorrhage intracranial	37.48	18.87	31	14696	28938	110545634
Pulpitis dental	36.97	18.87	12	14715	1537	110573035
Fatigue	35.23	18.87	68	14659	1215890	109358682
Autoimmune thyroiditis	34.66	18.87	17	14710	6417	110568155
Neurological decompensation	33.57	18.87	17	14710	6866	110567706
Upper gastrointestinal haemorrhage	33.09	18.87	37	14690	50059	110524513
Acute coronary syndrome	32.58	18.87	26	14701	23086	110551486
Incision site haematoma	32.42	18.87	7	14720	182	110574390
Altered state of consciousness	32.11	18.87	39	14688	57587	110516985
Toxicity to various agents	32	18.87	12	14715	480543	110094029
Eosinophilia	31.94	18.87	39	14688	57897	110516675
Rash maculo-papular	31.63	18.87	44	14683	74178	110500394
Haemoperitoneum	31.33	18.87	15	14712	5373	110569199
Device related bacteraemia	31.28	18.87	10	14717	1220	110573352
Drug hypersensitivity	30.81	18.87	11	14716	454079	110120493
Haemothorax	30.36	18.87	16	14711	7015	110567557
Pain	29.77	18.87	51	14676	954904	109619668
Coma	29.71	18.87	55	14672	117814	110456758
Abdominal discomfort	29.47	18.87	8	14719	393850	110180722
Haemorrhagic stroke	27.24	18.87	19	14708	13770	110560802
Autoimmune heparin-induced thrombocytopenia	26.73	18.87	5	14722	61	110574511
Joint swelling	26.39	18.87	13	14714	442832	110131740
Insomnia	25.74	18.87	8	14719	360582	110213990
Venous thrombosis limb	25.67	18.87	13	14714	5252	110569320
Rectal haemorrhage	25.43	18.87	52	14675	119781	110454791
Oesophageal candidiasis	25.41	18.87	17	14710	11517	110563055
Lumbosacral plexus injury	25.07	18.87	4	14723	17	110574555
Hepatic infarction	25.05	18.87	8	14719	973	110573599
Venous thrombosis	24.89	18.87	15	14712	8490	110566082
Primary adrenal insufficiency	24.12	18.87	7	14720	617	110573955
Pericardial mass	23.78	18.87	4	14723	25	110574547
Renal failure	23.53	18.87	75	14652	226499	110348073
Ecchymosis	23.36	18.87	19	14708	17319	110557253
Arterial haemorrhage	23.33	18.87	11	14716	3808	110570764
Leukocytosis	23.06	18.87	32	14695	53796	110520776
Infusion related reaction	22.99	18.87	11	14716	381151	110193421
Periodontitis	22.91	18.87	12	14715	5196	110569376
Haemodynamic instability	22.59	18.87	21	14706	22867	110551705
Procedural haemorrhage	22.44	18.87	12	14715	5415	110569157
Therapeutic product effect decreased	22.41	18.87	3	14724	244313	110330259
Cross sensitivity reaction	22.16	18.87	12	14715	5555	110569017
Shock	21.69	18.87	31	14696	53557	110521015
Haemarthrosis	21.64	18.87	13	14714	7316	110567256
Mobility decreased	21.58	18.87	3	14724	237419	110337153
Wheezing	21.46	18.87	4	14723	255226	110319346
Abdominal pain	21.45	18.87	129	14598	512860	110061712
Spinal cord compression	21.28	18.87	13	14714	7539	110567033
Nasal polyps	21.10	18.87	16	14711	13184	110561388
Postoperative wound complication	21.05	18.87	8	14719	1628	110572944
Cerebral haematoma	20.75	18.87	14	14713	9618	110564954
Electrocardiogram QT prolonged	20.47	18.87	45	14682	108915	110465657
Musculoskeletal stiffness	20.34	18.87	6	14721	279816	110294756
Brain stem haemorrhage	20.19	18.87	8	14719	1818	110572754
Gastric ulcer haemorrhage	20.16	18.87	14	14713	10080	110564492
Pericardial haemorrhage	20.08	18.87	11	14716	5206	110569366
Product dose omission issue	19.85	18.87	9	14718	321773	110252799
Intra-abdominal haemorrhage	19.84	18.87	11	14716	5331	110569241
Cerebellar haematoma	19.67	18.87	6	14721	628	110573944
Intraventricular haemorrhage	19.53	18.87	11	14716	5496	110569076
Depression	19.38	18.87	9	14718	317326	110257246
Hypoperfusion	18.93	18.87	9	14718	3172	110571400

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AX05	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents
MeSH PA	D000925	Anticoagulants
MeSH PA	D000991	Antithrombins
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D015842	Serine Proteinase Inhibitors
MeSH PA	D065427	Factor Xa Inhibitors
FDA MoA	N0000175635	Factor Xa Inhibitors
FDA EPC	N0000175637	Factor Xa Inhibitor
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:50249	anticoagulant
CHEBI has role	CHEBI:74518	anti-obesity agent

Related Drugs by ATC class:

B01AX Other antithrombotic agents 3 drugs

caplacizumab defibrotide dermatan sulfate

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Deep venous thrombosis	indication	128053003
Pulmonary thromboembolism	indication	233935004
Prevention of deep vein thrombosis	indication	439993001
Myocardial infarction	off-label use	22298006	DOID:5844
Acute coronary syndrome	off-label use	394659003
Diabetic retinopathy	contraindication	4855003	DOID:8947
Gastrointestinal ulcer	contraindication	40845000
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Operation on brain	contraindication	70586009
Heparin-induced thrombocytopenia	contraindication	73397007
Kidney disease	contraindication	90708001	DOID:557
Autoimmune thrombocytopenia	contraindication	128091003
Hemorrhagic cerebral infarction	contraindication	230706003
Local anesthetic intrathecal block	contraindication	231249005
Procedure on spine	contraindication	238181003
Anemia	contraindication	271737000	DOID:2355
Lumbar puncture	contraindication	277762005
Bacterial endocarditis	contraindication	301183007
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Surgical procedure on eye proper	contraindication	373353005
Hypertensive urgency	contraindication	443482000
Significant Bleeding	contraindication
Platelet Aggregation Inhibition	contraindication
Placement of Epidural Catheter	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.23	acidic
pKa2	0.94	acidic
pKa3	2.46	acidic
pKa4	3.08	acidic
pKa5	11.49	acidic
pKa6	11.98	acidic
pKa7	12.26	acidic
pKa8	12.43	acidic
pKa9	12.91	acidic
pKa10	13.69	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Antithrombin-III	Secreted	P01008	ANT3_HUMAN	ACTIVATOR	Kd	7.49		IUPHAR	CHEMBL
Coagulation factor X	Enzyme	P00742	FA10_HUMAN		IC50	7		CHEMBL

External reference:

ID	Source
4021296	VUID
N0000148733	NUI
D01844	KEGG_DRUG
114870-03-0	SECONDARY_CAS_RN
4021296	VANDF
C1098510	UMLSCUI
NTO	PDB_CHEM_ID
CHEMBL1201202	ChEMBL_ID
CHEMBL1200644	ChEMBL_ID
D000077425	MESH_DESCRIPTOR_UI
DB00569	DRUGBANK_ID
C049714	MESH_SUPPLEMENTAL_RECORD_UI
6819	IUPHAR_LIGAND_ID
J177FOW5JL	UNII
5282448	PUBCHEM_CID
321208	RXNORM
16268	MMSL
184641	MMSL
18938	MMSL
42652	MMSL
d04786	MMSL
009549	NDDF
009550	NDDF
385517000	SNOMEDCT_US
395236007	SNOMEDCT_US
708189008	SNOMEDCT_US
CHEBI:61033	CHEBI
7653	INN_ID
J177FOW5JL	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3443	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3454	INJECTION	5 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3465	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3476	INJECTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-154	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-155	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-156	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-157	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	28 sections
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5501	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA	27 sections
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5652	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-678	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-679	INJECTION	5 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-680	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-681	INJECTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-230	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-231	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-232	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-233	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-582	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-583	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-584	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-585	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Arixtra	HUMAN PRESCRIPTION DRUG LABEL	1	67457-592	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	NDA	32 sections
Arixtra	HUMAN PRESCRIPTION DRUG LABEL	1	67457-593	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA	32 sections
Arixtra	HUMAN PRESCRIPTION DRUG LABEL	1	67457-594	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA	32 sections
Arixtra	HUMAN PRESCRIPTION DRUG LABEL	1	67457-595	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	NDA	32 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1514	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1514	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1515	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1515	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections

Ask DrugCentral

Try a sample question

fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: